OBJECTIVE: To test the effect of patient-reported outcome (PRO)-based tele-health followup for tight control of disease activity in patients with rheumatoid arthritis (RA), and the differences between tele-health followup performed by rheumatologists or rheumatology nurses. METHODS: A total of 294 patients were randomized (1:1:1) to either PRO-based tele-health followup carried out by a nurse (PRO-TN) or a rheumatologist (PRO-TR), or conventional outpatient followup by physicians. The primary outcome was a change in the Disease Activity Score in 28 joints (DAS28) after week 52. Secondary outcomes were physical function, quality of life, and self-efficacy. The noninferiority margin was a DAS28 score change of 0.6. Mean differences were estimated following per protocol, intent-to-treat (ITT), and multivariate imputation analysis. RESULTS: Overall, patients had low disease activity at baseline and end followup. Demographics and baseline characteristics were similar between groups. Noninferiority was established for the DAS28. In the ITT analysis, mean differences in the DAS28 score between PRO-TR versus control were -0.10 (90% confidence interval [90% CI] -0.30, 0.13) and -0.19 (90% CI -0.41, 0.02) between PRO-TN versus control. When including 1 yearly visit to the outpatient clinic, patients in PRO-TN had mean ± SD 1.72 ± 1.03 visits/year, PRO-TR had 1.75 ± 1.03 visits/year, and controls had 4.15 ± 1.0 visits/year. This included extra visits due to inflammatory flare. CONCLUSION: Among RA patients with low disease activity or remission, a PRO-based tele-health followup for tight control of disease activity in RA can achieve similar disease control as conventional outpatient followup. The degree of disease control did not differ between patients seen by rheumatologists or rheumatology nurses.
RCT Entities:
OBJECTIVE: To test the effect of patient-reported outcome (PRO)-based tele-health followup for tight control of disease activity in patients with rheumatoid arthritis (RA), and the differences between tele-health followup performed by rheumatologists or rheumatology nurses. METHODS: A total of 294 patients were randomized (1:1:1) to either PRO-based tele-health followup carried out by a nurse (PRO-TN) or a rheumatologist (PRO-TR), or conventional outpatient followup by physicians. The primary outcome was a change in the Disease Activity Score in 28 joints (DAS28) after week 52. Secondary outcomes were physical function, quality of life, and self-efficacy. The noninferiority margin was a DAS28 score change of 0.6. Mean differences were estimated following per protocol, intent-to-treat (ITT), and multivariate imputation analysis. RESULTS: Overall, patients had low disease activity at baseline and end followup. Demographics and baseline characteristics were similar between groups. Noninferiority was established for the DAS28. In the ITT analysis, mean differences in the DAS28 score between PRO-TR versus control were -0.10 (90% confidence interval [90% CI] -0.30, 0.13) and -0.19 (90% CI -0.41, 0.02) between PRO-TN versus control. When including 1 yearly visit to the outpatient clinic, patients in PRO-TN had mean ± SD 1.72 ± 1.03 visits/year, PRO-TR had 1.75 ± 1.03 visits/year, and controls had 4.15 ± 1.0 visits/year. This included extra visits due to inflammatory flare. CONCLUSION: Among RApatients with low disease activity or remission, a PRO-based tele-health followup for tight control of disease activity in RA can achieve similar disease control as conventional outpatient followup. The degree of disease control did not differ between patients seen by rheumatologists or rheumatology nurses.
Authors: Pablo Rodríguez Sánchez-Laulhé; Luis Gabriel Luque-Romero; Francisco José Barrero-García; Ángela Biscarri-Carbonero; Jesús Blanquero; Alejandro Suero-Pineda; Alberto Marcos Heredia-Rizo Journal: JMIR Mhealth Uhealth Date: 2022-04-07 Impact factor: 4.947
Authors: Casper Webers; Esther Beckers; Annelies Boonen; Yvonne van Eijk-Hustings; Harald Vonkeman; Mart van de Laar; Astrid van Tubergen Journal: RMD Open Date: 2019-04-11
Authors: Birgith Engelst Grove; Per Ivarsen; Annette de Thurah; Liv Marit Schougaard; Derek Kyte; Niels Henrik Hjøllund Journal: BMC Health Serv Res Date: 2019-09-04 Impact factor: 2.655
Authors: Bryant R England; Claire E H Barber; Martin Bergman; Veena K Ranganath; Lisa G Suter; Kaleb Michaud Journal: Arthritis Care Res (Hoboken) Date: 2021-12 Impact factor: 5.178
Authors: Pablo Rodríguez-Sánchez-Laulhé; Luis Gabriel Luque-Romero; Jesús Blanquero; Alejandro Suero-Pineda; Ángela Biscarri-Carbonero; Francisco José Barrero-García; Alberto Marcos Heredia-Rizo Journal: Trials Date: 2020-09-10 Impact factor: 2.279